Bayer Escapes China Slowdown While Integrating Consumer Product Businesses
This article was originally published in The Tan Sheet
Executive Summary
OTC allergy remedies, contraceptive pills and skin care help Bayer continue its growth momentum in China despite an economic slowdown. Integrating OTC and TCM brands from local firm Dihon and global pharma Merck & Co., Bayer forecasts a smooth ride ahead.
You may also be interested in...
Dihon Acquisition Doubles Bayer’s Consumer Health Presence In China
Bayer acquired its second Chinese consumer health care firm to gain market share amid the country’s OTC consolidation trend. Dihon specializes in antifungal creams and herbal drugs for women’s and traditional Chinese medicines.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.